Blonanserin

CHEMBL178803 Phase 4 Aprovado Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

367.5 g/mol

LogP

5.5

Phase

4

An atypical antipsychotic used primarily in Japan and some other Asian countries to treat schizophrenia. It blocks dopamine D2 and D3 receptors as well as serotonin 5-HT2A receptors to reduce psychotic symptoms such as hallucinations and delusions. It has a lower tendency to cause certain metabolic side effects compared to some other antipsychotics.

Peso Molecular

367,5000 g/mol

LogP

5,50

TPSA

19,40 Å²

Regra dos 5 de Lipinski

Aprovado

Áreas Terapêuticas

Schizophrenia

Mecanismo de Ação

Blocks dopamine D2 receptors in the mesolimbic pathway, reducing excessive dopaminergic neurotransmission associated with psychotic symptoms. Many also antagonize serotonin 5-HT2A receptors, which may improve negative symptoms and reduce extrapyramidal side effects.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mecanismo

Blocks dopamine D2 receptors in the mesolimbic pathway, reducing excessive dopaminergic neurotransmission associated with psychotic symptoms. Many also antagonize serotonin 5-HT2A receptors, which may improve negative symptoms and reduce extrapyramidal …

Estrutura 2D

SVG PNG

Cite this structure

Embed this structure

SMILES

CCN1CCN(c2cc(-c3ccc(F)cc3)c3c(n2)CCCCCC3)CC1

InChI

InChI=1S/C23H30FN3/c1-2-26-13-15-27(16-14-26)23-17-21(18-9-11-19(24)12-10-18)20-7-5-3-4-6-8-22(20)25-23/h9-12,17H,2-8,13-16H2,1H3

Molecular Formula

C23H30FN3

HBD / HBA

- / 4

Ligações Rotacionáveis

3

Átomos Pesados

27

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Perguntas frequentes

An atypical antipsychotic used primarily in Japan and some other Asian countries to treat schizophrenia. It blocks dopamine D2 and D3 receptors as well as serotonin 5-HT2A receptors to reduce psychotic symptoms such as hallucinations and delusions. It has a lower tendency to cause certain metabolic side effects compared to some other antipsychotics.

Blocks dopamine D2 receptors in the mesolimbic pathway, reducing excessive dopaminergic neurotransmission associated with psychotic symptoms. Many also antagonize serotonin 5-HT2A receptors, which may improve negative symptoms and reduce extrapyramidal side effects.

Yes, Blonanserin is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL178803. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 125564. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

PillFYI

Procura informações acessíveis para o paciente?

Blonanserin no PillFYI

Estrutura

Dados Rápidos

Fórmula: C23H30FN3

Links Externos

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

Aviso Médico

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.